Jaguar health and napo pharmaceuticals announce acceptance of abstract for poster presentation at american society of clinical oncology annual meeting

San francisco, ca / accesswire / april 14, 2021 / jaguar health, inc. (nasdaq:jagx) today announced that an abstract associated with cancer therapy-related diarrhea ("ctd") by napo pharmaceuticals, inc. ("napo"), jaguar's wholly owned subsidiary, and napo's collaborators has been accepted for poster presentation at the american society of clinical oncology (asco®) annual meeting, which will be held virtually from june 4-8, 2021. two other ctd-related abstracts from napo and its collaborators have also been accepted for online publication for the 2021 asco annual meeting.
JAGX Ratings Summary
JAGX Quant Ranking